• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠长期并发症中的血栓栓塞

Thromboembolism in the Complications of Long COVID-19.

作者信息

Lopes Leilani A, Agrawal Devendra K

机构信息

Western University of Health Sciences, College of Osteopathic Medicine of the Pacific - Northwest, Lebanon.

Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, Pomona, CA.

出版信息

Cardiol Cardiovasc Med. 2023;7(2):123-128. doi: 10.26502/fccm.92920317. Epub 2023 Apr 20.

DOI:10.26502/fccm.92920317
PMID:37389402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10310316/
Abstract

SARS-CoV-2 is a +ssRNA helical coronavirus responsible for the global pandemic caused by coronavirus disease 19 (COVID-19). Classical clinical symptoms from primary COVID-19 when symptomatic include cough, fever, pneumonia or even ARDS; however, they are limited primarily to the respiratory system. Long-COVID-19 sequalae is responsible for many pathologies in almost every organ system and may be present in up to 30% of patients who have developed COVID-19. Our review focuses on how long-COVID-19 (3 -24 weeks after primary symptoms) may lead to an increased risk for stroke and thromboembolism. Patients who were found to be primarily at risk for thrombotic events included critically ill and immunocompromised patients. Additional risk factors for thromboembolism and stroke included diabetes, hypertension, respiratory and cardiovascular disease, and obesity. The etiology of how long-COVID-19 leads to a hypercoagulable state are yet to be definitively elucidated. However, anti-phospholipid antibodies and elevated D-dimer are present in many patients who develop thromboembolism. In addition, chronic upregulation and exhaustion of the immune system may lead to a pro-inflammatory and hypercoagulable state, increasing the likelihood for induction of thromboembolism or stroke. This article provides an up-to-date review on the proposed etiologies for thromboembolism and stroke in patients with long-COVID-19 and to assist health care providers in examining patients who may be at a higher risk for developing these pathologies.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种正链单股RNA螺旋状冠状病毒,可引发由冠状病毒病19(COVID-19)导致的全球大流行。有症状的原发性COVID-19的典型临床症状包括咳嗽、发热、肺炎甚至急性呼吸窘迫综合征;然而,这些症状主要局限于呼吸系统。长期COVID-19后遗症会导致几乎每个器官系统出现多种病变,在感染COVID-19的患者中,高达30%的人可能会出现这些后遗症。我们的综述重点关注长期COVID-19(主要症状出现后3至24周)如何可能导致中风和血栓栓塞风险增加。被发现主要有血栓形成事件风险的患者包括重症患者和免疫功能低下患者。血栓栓塞和中风的其他风险因素包括糖尿病、高血压、呼吸系统和心血管疾病以及肥胖。长期COVID-19导致高凝状态的病因尚未完全阐明。然而,许多发生血栓栓塞的患者体内存在抗磷脂抗体和D-二聚体升高的情况。此外,免疫系统的慢性上调和耗竭可能导致促炎和高凝状态,增加引发血栓栓塞或中风的可能性。本文对长期COVID-患者血栓栓塞和中风的拟议病因进行了最新综述,以帮助医疗保健提供者检查可能有更高风险发生这些病变的患者。

相似文献

1
Thromboembolism in the Complications of Long COVID-19.新冠长期并发症中的血栓栓塞
Cardiol Cardiovasc Med. 2023;7(2):123-128. doi: 10.26502/fccm.92920317. Epub 2023 Apr 20.
2
COVID-19 and Thromboinflammation: Is There a Role for Statins?COVID-19 与血栓炎症:他汀类药物有作用吗?
Clinics (Sao Paulo). 2021 Mar 24;76:e2518. doi: 10.6061/clinics/2021/e2518. eCollection 2021.
3
IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).白细胞介素-1(IL-1)在 COVID-19 中诱导血栓烷 A2(TxA2)的产生,导致炎症和微血栓形成:白细胞介素-1 受体拮抗剂(IL-1Ra)的抑制作用。
J Biol Regul Homeost Agents. 2020;34(5):1623-1627. doi: 10.23812/20-34-4EDIT-65.
4
Venous thromboembolism in patients with COVID-19. A prevalent and a preventable complication of the pandemic.新型冠状病毒肺炎患者的静脉血栓栓塞症。这是该大流行病一种常见且可预防的并发症。
J Interv Med. 2021 May;4(2):62-65. doi: 10.1016/j.jimed.2021.02.006. Epub 2021 Feb 26.
5
Thromboelastography findings in critically ill COVID-19 patients.危重症COVID-19患者的血栓弹力图检查结果
J Thromb Thrombolysis. 2021 May;51(4):961-965. doi: 10.1007/s11239-020-02300-7. Epub 2020 Oct 4.
6
Incidence of Venous Thromboembolism in Critically Ill Coronavirus Disease 2019 Patients Receiving Prophylactic Anticoagulation.新冠肺炎危重症患者预防性抗凝治疗的静脉血栓栓塞症发生率。
Crit Care Med. 2020 Sep;48(9):e805-e808. doi: 10.1097/CCM.0000000000004472.
7
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
8
A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study.一名52岁新冠病毒检测呈阳性男子在接种强生疫苗后出现静脉血栓栓塞和弥散性血管内凝血:病例研究
Cureus. 2021 Jul 14;13(7):e16383. doi: 10.7759/cureus.16383. eCollection 2021 Jul.
9
Hematological manifestations and complications of COVID-19.COVID-19 的血液学表现和并发症。
Adv Clin Exp Med. 2021 Jan;30(1):101-107. doi: 10.17219/acem/130604.
10
Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.COVID-19 患者的动脉和静脉血栓栓塞并发症登记册。
J Am Coll Cardiol. 2020 Nov 3;76(18):2060-2072. doi: 10.1016/j.jacc.2020.08.070.

引用本文的文献

1
Management of Venous Thromboembolism After Hip and Knee Arthroplasty.髋关节和膝关节置换术后静脉血栓栓塞的管理
J Orthop Sports Med. 2025;7(3):311-327. doi: 10.26502/josm.511500210. Epub 2025 Jul 7.
2
Distinct platelet transcriptomic heterogeneity in respiratory illnesses and modulation by corticosteroids and immune antibody treatments.呼吸道疾病中独特的血小板转录组异质性以及皮质类固醇和免疫抗体治疗的调节作用。
J Transl Med. 2025 Aug 19;23(1):935. doi: 10.1186/s12967-025-06845-0.
3
Nutrition, Gut Microbiota, and Epigenetics in the Modulation of Immune Response and Metabolic Health.营养、肠道微生物群与表观遗传学对免疫反应和代谢健康的调节作用
Cardiol Cardiovasc Med. 2025;9(3):111-124. Epub 2025 May 5.
4
Role of Gut Microbiota in Long COVID: Impact on Immune Function and Organ System Health.肠道微生物群在长期新冠中的作用:对免疫功能和器官系统健康的影响
Arch Microbiol Immunol. 2025;9(1):38-53. Epub 2025 Feb 4.
5
Strategies to Minimize Virus Transmission During Anesthesia Procedures in COVID-19 Patients.新冠肺炎患者麻醉过程中减少病毒传播的策略。
Anesth Crit Care. 2024;6(4):48-59. doi: 10.26502/acc.071. Epub 2024 Oct 23.
6
Etiology, Pathophysiology, and Treatment Strategies in the Prevention and Management of Metabolic Syndrome.代谢综合征预防与管理中的病因、病理生理学及治疗策略
Arch Intern Med Res. 2024;7(4):273-283. doi: 10.26502/aimr.0184. Epub 2024 Oct 28.
7
Computational Biology in the Discovery of Biomarkers in the Diagnosis, Treatment and Management of Cardiovascular Diseases.计算生物学在心血管疾病诊断、治疗和管理中生物标志物发现方面的应用
Cardiol Cardiovasc Med. 2024;8(5):405-414. Epub 2024 Sep 5.
8
Evaluation of d-dimer as outcome biomarker in COVID-19 acute respiratory distress patients.评估 D-二聚体作为 COVID-19 急性呼吸窘迫患者的结局生物标志物。
Rev Inst Med Trop Sao Paulo. 2024 Sep 23;66:e57. doi: 10.1590/S1678-9946202466057. eCollection 2024.
9
Epidemiology, Pathophysiology, and Current Treatment Strategies in Stroke.中风的流行病学、病理生理学及当前治疗策略
Cardiol Cardiovasc Med. 2024;8(4):389-404. doi: 10.26502/fccm.92920399. Epub 2024 Aug 29.
10
The Long-Term Cardiovascular Impact of COVID-19: Pathophysiology, Clinical Manifestations, and Management.新冠病毒病的长期心血管影响:病理生理学、临床表现及管理
Cureus. 2024 Aug 10;16(8):e66554. doi: 10.7759/cureus.66554. eCollection 2024 Aug.

本文引用的文献

1
Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies.新型冠状病毒肺炎疫苗接种的不良血液学效应及血液系统恶性肿瘤患者获得性免疫低下的发病机制
Vaccines (Basel). 2023 Mar 15;11(3):662. doi: 10.3390/vaccines11030662.
2
Role of sirtuins in attenuating plaque vulnerability in atherosclerosis.沉默信息调节因子 2 相关酶在动脉粥样硬化斑块易损性减弱中的作用。
Mol Cell Biochem. 2024 Jan;479(1):51-62. doi: 10.1007/s11010-023-04714-2. Epub 2023 Mar 23.
3
Residual risks and evolving atherosclerotic plaques.残留风险与不断演变的动脉粥样硬化斑块。
Mol Cell Biochem. 2023 Dec;478(12):2629-2643. doi: 10.1007/s11010-023-04689-0. Epub 2023 Mar 10.
4
Role of oncostatin-M in ECM remodeling and plaque vulnerability.基质金属蛋白酶在 ECM 重塑和斑块易损性中的作用。
Mol Cell Biochem. 2023 Nov;478(11):2451-2460. doi: 10.1007/s11010-023-04673-8. Epub 2023 Mar 1.
5
Characterizing and Predicting Post-Acute Sequelae of SARS CoV-2 Infection (PASC) in a Large Academic Medical Center in the US.美国一家大型学术医疗中心对新冠病毒感染后急性后遗症(PASC)的特征描述与预测
J Clin Med. 2023 Feb 7;12(4):1328. doi: 10.3390/jcm12041328.
6
Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records.2019冠状病毒病住院患者的血栓栓塞事件发生率及死亡率:电子健康记录的大型观察性队列研究
TH Open. 2022 Nov 18;6(4):e408-e420. doi: 10.1055/a-1937-9692. eCollection 2022 Oct.
7
Heterogeneous Population of Immune cells Associated with Early Thrombosis in Arteriovenous Fistula.与动静脉内瘘早期血栓形成相关的免疫细胞异质性群体
J Surg Res (Houst). 2022;5(3):423-434. doi: 10.26502/jsr.10020237. Epub 2022 Jul 7.
8
Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics.肠道-大脑通讯在 COVID-19 中的作用:分子机制、介质、生物标志物和治疗方法。
Expert Rev Clin Immunol. 2022 Sep;18(9):947-960. doi: 10.1080/1744666X.2022.2105697. Epub 2022 Jul 28.
9
Immune response to SARS-CoV-2 in severe disease and long COVID-19.重症疾病和新冠长期症状中对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的免疫反应。
iScience. 2022 Aug 19;25(8):104723. doi: 10.1016/j.isci.2022.104723. Epub 2022 Jul 4.
10
Innate and adaptive immune cells associate with arteriovenous fistula maturation and failure.先天性和适应性免疫细胞与动静脉内瘘的成熟和失败相关。
Can J Physiol Pharmacol. 2022 Aug 1;100(8):716-727. doi: 10.1139/cjpp-2021-0731. Epub 2022 Jun 7.